Syschem
SYSCHEMINDIALTD NSE
Syschem
HealthcareNSE: SYSCHEMINDIALTD BSE: 531173 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹164 Cr
Volatility
Moderate
P/E Ratio
26.8
EBITDA
₹21.10 Cr
Return on Equity
0.5%
Debt to Equity
0
Book Value
₹26.86
EPS
₹0.31
52W High
₹61
52W Low
₹29.29
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
6- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 32.4% CAGR over last 5 years
- Promoter holding has increased by 2.52% over last quarter.
- Company's median sales growth is 70.0% of last 10 years
- Company's working capital requirements have reduced from 40.8 days to 29.3 days
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.41% over last 3 years.
- Contingent liabilities of Rs.50.2 Cr.
Growth Rate
Revenue Growth
48.53% lower than
3Y
Net Income Growth
—
Cash Flow Change
60.66% higher than
3Y
ROE
-89.69% lower than
3Y
ROCE
-82.13% higher than
3Y
EBITDA Margin (Avg.)
254% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.1 | 37.11 | 43.74 | 74.71 | 87.53 | 47.52 | 77.76 | 119 | 109 | 104 | 142 | 219 | 109 |
| Expenses | 40.65 | 35.26 | 42.66 | 73.09 | 86.72 | 47.45 | 76.56 | 117 | 107 | 100 | 136 | 210 | 109 |
| Operating Profit | 2.45 | 1.85 | 1.08 | 1.62 | 0.81 | 0.07 | 1.2 | 1.9 | 2.46 | 3.3 | 5.96 | 9.37 | 0.54 |
| OPM % | 5.68% | 4.99% | 2.47% | 2.17% | 0.93% | 0.15% | 1.54% | 1.6% | 2.25% | 3.19% | 4.21% | 4.27% | 0.49% |
| Other Income | 0 | 0 | 0.01 | 0.15 | 0.01 | 0 | 0.02 | 0.02 | 0.01 | 0.01 | 0 | 0 | 0.05 |
| Interest | 0.1 | 0.03 | 0.11 | 0.01 | 0 | 0.03 | 0.04 | 0 | 0.04 | 0.01 | 0.17 | 2.04 | 0.49 |
| Depreciation | 0.68 | 0.7 | 0.74 | 0.67 | 0.68 | 0.68 | 0.68 | 0.91 | 0.76 | 0.76 | 0.82 | 1.73 | 1.56 |
| PBT | 1.67 | 1.12 | 0.24 | 1.09 | 0.14 | -0.64 | 0.5 | 1.01 | 1.67 | 2.54 | 4.97 | 5.6 | -1.46 |
| Tax % | 0% | 0% | 0% | 123.85% | 0% | 0% | 0% | 54.46% | 0% | 25.59% | 15.9% | 68.93% | 15.07% |
| Net Profit | 1.68 | 1.12 | 0.23 | -0.26 | 0.14 | -0.64 | 0.5 | 0.46 | 1.67 | 1.9 | 4.17 | 1.74 | -1.67 |
| EPS in Rs | 0.42 | 0.28 | 0.06 | -0.07 | 0.04 | -0.16 | 0.13 | 0.11 | 0.38 | 0.44 | 0.96 | 0.36 | -0.34 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 199 | 332 | 574 | 574 |
| Expenses | 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 192 | 328 | 553 | 554 |
| Operating Profit | -3 | -1 | 0 | 3 | 4 | 0 | -5 | 1 | 9 | 7 | 4 | 21 | 19 |
| OPM % | -23% | -24% | 0.4% | 4.5% | 4.4% | -0.1% | -7% | 0.9% | 8% | 3.5% | 1.2% | 3.7% | 3.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| PBT | -5 | -3 | -2 | 1 | 2 | -2 | -7 | -2 | 6 | 4 | 1 | 15 | 12 |
| Tax % | -26% | -27% | -30% | 43% | 50% | -16% | -24% | -22% | 27% | 33% | 54% | 26% | — |
| Net Profit | -4 | -2 | -1 | 0 | 1 | -2 | -6 | -2 | 5 | 3 | 0 | 11 | 6 |
| EPS in Rs | -1.94 | -1.13 | -0.75 | 0.17 | 0.32 | -0.79 | -2.07 | -0.59 | 1.13 | 0.69 | 0.11 | 2.23 | 1.42 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 40 | 44 | 49 |
| Reserves | -6 | -8 | -10 | -8 | -8 | -10 | -15 | -16 | -10 | 17 | 48 | 73 |
| Borrowings | 28 | 27 | 22 | 20 | 16 | 17 | 16 | 2 | 2 | 0 | 0 | 0 |
| Other Liabilities | 13 | 12 | 16 | 29 | 35 | 36 | 55 | 51 | 69 | 107 | 126 | 169 |
| Total Liabilities | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
| Fixed Assets | 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 31 | 53 | 68 |
| CWIP | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 129 | 164 | 224 |
| Total Assets | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1 | 0 | 6 | 0 | -2 | 3 | 4 | 1 | -8 | -26 | -10 | 8 |
| Investing | 0 | 0 | 0 | 0 | 2 | -4 | -4 | -1 | -2 | -6 | -22 | -20 |
| Financing | -2 | -1 | -7 | 0 | 0 | 0 | 0 | 0 | 11 | 32 | 34 | 18 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
| Free Cash Flow | 1 | 0 | 6 | -1 | -2 | 0 | -1 | -2 | -10 | -32 | -32 | -11 |
| CFO/OP | -56 | -53 | 12,760 | 9 | -24 | -3,456 | -40 | 107 | -79 | -348 | -238 | 54 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 | 126 | 99 | 92 |
| Inventory Days | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 | 107 | 81 | 41 |
| Days Payable | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 | 198 | 143 | 112 |
| Cash Conversion Cycle | 124 | 271 | -119 | -24 | -7 | -19 | 9 | -14 | 38 | 34 | 36 | 21 |
| Working Capital Days | -139 | -564 | -319 | -50 | -20 | -36 | -1 | -15 | 48 | 54 | 39 | 29 |
| ROCE % | -11% | -8% | -6% | 3% | 7% | -8% | -29% | -12% | 38% | 11% | 1% | 16% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Syschem insights
65 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Board Meeting Intimation for Intimation Of Board Meeting Dated 25Th May, 2026.
29 Apr - Board meets on 25 May 2026 to approve FY26 audited results and appoint internal auditor. 29 Apr - Board meets on 25 May 2026 to approve FY26 audited results and appoint internal auditor.
2
Board Meeting Intimation for Intimation Of Board Meeting Dated 25Th May, 2026.
29 Apr - Board meets on 25 May 2026 to approve FY26 audited results and appoint internal auditor. 29 Apr - Board meets on 25 May 2026 to approve FY26 audited results and appoint internal auditor.
3
Compliance_ Regulation 32 For The Quarter Ending 31St March, 2026.
27 Apr - Syschem reports no deviation in use of Rs.20.21 crore preferential issue proceeds for quarter ended 31 March 2026. 27 Apr - Syschem reports no deviation in use of Rs.20.21 crore preferential issue proceeds for quarter ended 31 March 2026.
4
Compliance_ Regulation 32 For The Quarter Ending 31St March, 2026.
15h - Syschem reports no deviation in use of Rs.20.21 crore preferential issue proceeds for quarter ended 31 March 2026. 15h - Syschem reports no deviation in use of Rs.20.21 crore preferential issue proceeds for quarter ended 31 March 2026.
5
Announcement Under Regulation 30
15 Apr - Company reported cyber fraud and unauthorized transfer of Rs 1.96 crore on 15-04-2026. 15 Apr - Company reported cyber fraud and unauthorized transfer of Rs 1.96 crore on 15-04-2026.
1
Shareholder Meeting/Postal Ballot: Newspaper Advertisements After Dispatch Of Notice To The Shareholders. 4 Sept 2026
General_Announcements
4
Newspaper Advertisements As Per Regulation 47 Of SEBI(Listing Obligations And Disclosure Requirements) 2015. 2 Sept 2026
General_Announcements
Frequently Asked Questions about Syschem
What does Syschem (India) Ltd do?
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.[1]
Where is Syschem (India) Ltd (531173) listed?
Syschem (India) Ltd trades as SYSCHEMINDIALTD on the NSE and under code 531173 on the BSE.
Which sector does Syschem (India) Ltd belong to?
Syschem (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Syschem (India) Ltd?
Syschem (India) Ltd has a market capitalisation of ₹163.5 Cr, which places it in the Small Cap band.
What is the PE ratio of Syschem (India) Ltd?
Syschem (India) Ltd trades at a PE ratio of 26.80, on earnings per share of ₹0.31, against a book value of ₹26.86 per share.
What is the 52-week high and low of Syschem (India) Ltd?
Over the last 52 weeks Syschem (India) Ltd has traded between ₹29.29 and ₹61.
What is the Return on Equity (ROE) of Syschem (India) Ltd?
Syschem (India) Ltd reported a return on equity of 0.50%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.[1]
Website syschem.in
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531173.md for Syschem (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.